A Bristol Myers product in 1909
From The New England Council (newenglandcouncil.com)
“Bristol Myers Squibb, a New York-based biopharmaceutical company, recently added a 244,000-square-foot expansion to its Devens, Mass., facility to further the company’s efforts to battle cancer. The new addition is expected to begin operations by the end of the year and will be at the forefront of cancer technology for producing Breyanzi, a CAR-T cell therapy designed to treat lymphoma in patients.
“CAR-T cell therapy is a highly specialized process involving genetically modified cells that are personalized to attack a patient’s cancer cells. It generally takes weeks to isolate, freeze, dilute, and monitor the modified cells before the patient can receive an infusion. Though Breyanzi only recently won FDA approval in February 2021 and is a relatively new technology, the Devens expansion seeks to enhance CAR-T cell manufacturing capability for Bristol Myers-Squibb. The site is also expected to add hundreds of jobs.
“Krishnan Viswanadhan, a senior vice president for the company’s global cell therapy franchise, stated, ‘I’m really excited about what cell therapy has to offer.’’’
Read more from the Worcester Business Journal.
Devens is a regional enterprise zone and Census-designated place in the towns of Ayer and Shirley, in Middlesex County, and Harvard, in Worcester County, Massachusetts. It is the successor to Fort Devens, a military post that operated from 1917 to 1996. The population was 1,840 at the 2010 census.
Street scene at Fort Devens in the early 20th Century
Fort Devens Military Cemetery
